Evaluating drug treatments for Parkinson's disease: how good are the trials?

Wheatley, Keith, Stowe, Rebecca L., Clarke, Carl E., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Williams, Adrian C. and Gray, Richard 2002. Evaluating drug treatments for Parkinson's disease: how good are the trials? British Medical Journal 324 (7352) , pp. 1508-1511.

Preview

PDF - Published Version Download (216kB) | Preview

Abstract

The prevalence of Parkinson's disease will increase as the population ages, making it important to identify reliably the most effective drug therapy Although many randomised controlled trials have evaluated the efficacy of different classes of drugs in both early and later Parkinson's disease, uncertainty about best treatment remains because of small numbers, inadequate follow up, and inappropriate end points Much larger trials are needed with long term follow up and end points of relevance to patients Large simple pragmatic trials have improved treatment of heart disease, stroke, and cancer and their methods should be applied to Parkinson's disease and other neurodegenerative diseases

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Subjects:	R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry R Medicine > RM Therapeutics. Pharmacology
Additional Information:	Pdf uploaded in accordance with publisher's policy at http://www.sherpa.ac.uk/romeo/issn/0959-8138/ (accessed 26/02/2014)
Publisher:	BMJ Publishing Group
ISSN:	0267-0623
Date of First Compliant Deposit:	30 March 2016
Last Modified:	24 May 2023 16:30
URI:	https://orca.cardiff.ac.uk/id/eprint/49705

Actions (repository staff only)

Edit Item